QIHC common mistakes
QIHC · Understand the traps and how to avoid them.
Applies a single fixation rule to every specimen type - e.g., states that 'all tissues need 6–24 hours in formalin' and gives the same answer for a 1 mm needle core and a 20 mm resection, without invoking the ~1 mm/hour formalin penetration rate or the 10:1 fixative-to-tissue volume ratio.
The 6–24 hour figure is the most memorized number in the preanalytic domain, so candidates quote it as an absolute and never link it to specimen thickness, density, or time-to-fixation. Question stems that change the specimen size are then answered with the memorized number instead of the principle.
What to do instead
Anchor every fixation answer to three variables: penetration rate (~1 mm/hr from the surface inward), fixative volume ratio (10:1), and delay before fixation (ischemia time). Practice by writing the fixation time you would specify for a core biopsy, a 4 mm punch, and a 2 cm lumpectomy and justifying each with the penetration rate.
Assumes decalcified bone, frozen sections, and cytology cell blocks behave like routine FFPE and applies the same retrieval and antibody protocol, or claims decalcification 'has no effect' on IHC.
Routine FFPE is the mental default, so specimen-specific preanalytic damage (acid decalcification stripping epitopes, air-drying in frozen sections causing cytoplasmic smearing, alcohol-fixed smears requiring different retrieval) gets overlooked when the stem describes a non-routine preparation.
What to do instead
Build a short matrix of specimen type → preanalytic risk → adjustment: strong-acid decalcification degrades many epitopes and favors EDTA-based decalcification; frozen sections usually need no or minimal HIER and are prone to drying artifact; alcohol-fixed material often needs different retrieval than NBF-fixed. Review this matrix before the exam rather than memorizing single protocols.
Treats antigen retrieval as one-size-fits-all - always selects citrate pH 6 or always selects EDTA pH 9 regardless of the antibody and clone - and cannot explain why the choice is antibody-specific.
Candidates memorize a single 'best' retrieval condition (often pH 9 EDTA because it is frequently cited as more effective) and then apply it universally, missing that retrieval optimum is an empirical property of each antibody–epitope pair, not a general rule.
What to do instead
Learn retrieval as a per-antibody optimization: nuclear antigens such as ER, PR, and Ki-67 generally perform well with high-pH EDTA, while many cytoplasmic and some membranous targets do best with citrate pH 6; the definitive source is the validated protocol for that specific clone. On the exam, when a stem gives you a validated protocol, follow it rather than substituting your preferred buffer.
States that avidin–biotin complex (ABC) methods are more sensitive than compact polymer detection, or dismisses biotin-related background as impossible in a polymer system.
Older textbook hierarchies are memorized as fixed facts, and candidates do not update them for micro-polymer technology, which achieves high sensitivity without avidin–biotin and therefore avoids endogenous biotin interference (relevant in liver, kidney, and tissues rich in biotin).
What to do instead
Learn the current detection hierarchy - direct < indirect < ABC/LSAB < compact/micro-polymer - and attach the trade-off to each: polymers give better sensitivity and less endogenous biotin interference, but can suffer from steric crowding with large multimers and still require species-matched negative controls. Expect exam items that test the 'why,' not just the ranking.
Designs or evaluates a multiplex/double-stain protocol using two antibodies raised in the same species, or from the same host species with no blocking or denaturation step, and does not consider cross-reactivity or the order in which chromogens and elution steps are applied.
Multiplexing is often studied only as 'use two chromogens,' so the species-combination logic, sequential denaturation, and steric/chromogen-contrast constraints are skipped. Candidates then accept a protocol that would produce uninterpretable mixed staining.
What to do instead
For every double-stain scenario, write out: host species of each primary (must be different, or a denaturation/blocking step must be specified), which target is stained first (usually the less abundant or nuclear target, with the more robust chromogen), and which chromogens give contrast without overlapping localization. If the same species is required, state the elution or denaturation step explicitly.
Declares a run valid on the sole basis that 'the positive control stained,' without checking that the control tissue expresses the target at the expected intensity and subcellular pattern, that it was fixed and processed like the patient tissue, or that an appropriate negative reagent control (isotype-matched for monoclonal antibodies) was included.
Control logic is studied as a checklist of control types rather than as an inference problem. Candidates therefore treat any positivity in the control as proof of validity, missing that a weak or aberrantly localized control signal may indicate a failed run that happened to retain faint staining.
What to do instead
Practice the two-question control algorithm: (1) Did the positive control show the expected intensity AND the expected subcellular pattern (nuclear vs cytoplasmic vs membranous)? (2) Did the negative reagent/negative tissue control stay clean? Then compare control and patient tissue fixation and processing. If the positive control is weak or wrongly localized, the run is invalid and the patient result cannot be interpreted regardless of how the patient tissue looks.
Reports a result without applying the validated scoring criteria - e.g., calling HER2 2+ 'positive,' calling ER positive at <1% under current criteria, or reporting PD-L1 without stating the assay, clone, and scoring system used.
Scoring systems are memorized as raw numbers rather than as decision rules tied to a specific guideline version and a specific companion assay, so equivocal categories collapse into positive/negative and the reporting requirement to name the antibody clone and platform is forgotten.
What to do instead
Learn each major marker as a decision tree with its equivocal branch: HER2 (0/1+/2+/3+, with 2+ requiring ISH reflex), ER/PR (percentage plus intensity, with the <1% threshold), and PD-L1 (name the clone, platform, and scoring algorithm, since scores are not interchangeable across assays). Always include clone, detection system, and control performance in the report.
When staining is weak or absent, immediately proposes increasing antibody concentration or switching detection systems, instead of first reading the controls to localize the failure.
Weak staining feels like an antibody problem, so candidates jump to the reagent they can adjust. The control result is the fastest discriminator, and skipping it leads to changing the wrong variable and masking the real cause (e.g., overfixation or a failed retrieval step).
What to do instead
Use a fixed troubleshooting order: (1) Is the positive control weak too? If yes, the problem is in the run - retrieval, detection, chromogen, or reagent - and antibody concentration is not the first fix. (2) Is the positive control strong but the patient tissue negative? Then the problem is preanalytic in that specimen (fixation, processing, decalcification) or the target is genuinely absent. Only after both controls are correct do you titrate the primary.
Interprets edge staining, a rim of cytoplasmic blush, or signal over necrotic debris as true positivity, or conversely dismisses genuine peripheral staining as artifact.
Edge and background artifacts are learned as a list of pictures rather than as mechanisms, so the candidate cannot tell whether a finding is drying/retraction artifact (sharp, involves only the outermost rim, absent deeper in the section) or true staining (follows cell morphology and is reproduced in the positive control).
What to do instead
Learn the mechanism-to-pattern mapping: drying and retraction artifact is restricted to the tissue edge and does not follow cellular architecture; nonspecific background from incomplete blocking or endogenous peroxidase tends to be diffuse and cytoplasmic; necrotic debris traps chromogen non-specifically. Confirm a genuine edge signal by checking that it follows cell morphology and that the positive control shows the expected pattern.
Describes DAB as safe to discard down the sink, states that any IHC assay run with an FDA-cleared antibody is itself FDA-cleared, or treats an analyte-specific reagent (ASR) as a complete in vitro diagnostic kit.
Safety and regulatory content is treated as low-yield trivia and read once, so the candidate conflates categories: ASR (a component with no performance claims), IVD kit (with cleared indications), and laboratory-developed test (LDT) under CLIA - the last of which most IHC assays actually are.
What to do instead
Memorize the regulatory triad: ASR = reagent component, no claims, lab must establish performance; IVD = cleared for stated use; LDT = designed, validated, and verified by the laboratory under CLIA. Separately fix the disposal rule: DAB is a suspected carcinogen and must be collected and disposed of as hazardous waste, never drain-disposed; handle formaldehyde per OSHA exposure limits and xylene as a flammable hazardous solvent.